BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. Int J Clin Oncol 2021;26:1506-13. [PMID: 34023933 DOI: 10.1007/s10147-021-01936-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Tural D, Arslan C, Selcukbiricik F, Olmez OF, Akar E, Erman M, Ürün Y, Erdem D, Karadurmus N, Kilickap S. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice. Clin Genitourin Cancer 2022:S1558-7673(22)00256-7. [PMID: 36641357 DOI: 10.1016/j.clgc.2022.11.019] [Reference Citation Analysis]
2 Tassinari E, Mollica V, Nuvola G, Marchetti A, Rosellini M, Massari F. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy. Cancer Manag Res 2022;14:1945-60. [PMID: 35720644 DOI: 10.2147/CMAR.S287904] [Reference Citation Analysis]